-
Scaffold Splits Overestimate Virtual Screening Performance
Authors:
Qianrong Guo,
Saiveth Hernandez-Hernandez,
Pedro J Ballester
Abstract:
Virtual Screening (VS) of vast compound libraries guided by Artificial Intelligence (AI) models is a highly productive approach to early drug discovery. Data splitting is crucial for better benchmarking of such AI models. Traditional random data splits produce similar molecules between training and test sets, conflicting with the reality of VS libraries which mostly contain structurally distinct c…
▽ More
Virtual Screening (VS) of vast compound libraries guided by Artificial Intelligence (AI) models is a highly productive approach to early drug discovery. Data splitting is crucial for better benchmarking of such AI models. Traditional random data splits produce similar molecules between training and test sets, conflicting with the reality of VS libraries which mostly contain structurally distinct compounds. Scaffold split, grou** molecules by shared core structure, is widely considered to reflect this real-world scenario. However, here we show that the scaffold split also overestimates VS performance. The reason is that molecules with different chemical scaffolds are often similar, which hence introduces unrealistically high similarities between training molecules and test molecules following a scaffold split. Our study examined three representative AI models on 60 NCI-60 datasets, each with approximately 30,000 to 50,000 molecules tested on a different cancer cell line. Each dataset was split with three methods: scaffold, Butina clustering and the more accurate Uniform Manifold Approximation and Projection (UMAP) clustering. Regardless of the model, model performance is much worse with UMAP splits from the results of the 2100 models trained and evaluated for each algorithm and split. These robust results demonstrate the need for more realistic data splits to tune, compare, and select models for VS. For the same reason, avoiding the scaffold split is also recommended for other molecular property prediction problems. The code to reproduce these results is available at https://github.com/ScaffoldSplitsOverestimateVS
△ Less
Submitted 30 June, 2024; v1 submitted 2 June, 2024;
originally announced June 2024.
-
Stochastic-based Neural Network hardware acceleration for an efficient ligand-based virtual screening
Authors:
Christian F. Frasser,
Carola de Benito,
Vincent Canals,
Miquel Roca,
Pedro J. Ballester,
Josep L. Rossello
Abstract:
Artificial Neural Networks (ANN) have been popularized in many science and technological areas due to their capacity to solve many complex pattern matching problems. That is the case of Virtual Screening, a research area that studies how to identify those molecular compounds with the highest probability to present biological activity for a therapeutic target. Due to the vast number of small organi…
▽ More
Artificial Neural Networks (ANN) have been popularized in many science and technological areas due to their capacity to solve many complex pattern matching problems. That is the case of Virtual Screening, a research area that studies how to identify those molecular compounds with the highest probability to present biological activity for a therapeutic target. Due to the vast number of small organic compounds and the thousands of targets for which such large-scale screening can potentially be carried out, there has been an increasing interest in the research community to increase both, processing speed and energy efficiency in the screening of molecular databases. In this work, we present a classification model describing each molecule with a single energy-based vector and propose a machine-learning system based on the use of ANNs. Different ANNs are studied with respect to their suitability to identify biochemical similarities. Also, a high-performance and energy-efficient hardware acceleration platform based on the use of stochastic computing is proposed for the ANN implementation. This platform is of utility when screening vast libraries of compounds. As a result, the proposed model showed appreciable improvements with respect previously published works in terms of the main relevant characteristics (accuracy, speed and energy-efficiency).
△ Less
Submitted 3 June, 2020;
originally announced June 2020.
-
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties
Authors:
Michael P. Menden,
Francesco Iorio,
Mathew Garnett,
Ultan McDermott,
Cyril Benes,
Pedro J. Ballester,
Julio Saez-Rodriguez
Abstract:
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses. Various computational approaches have been…
▽ More
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses. Various computational approaches have been proposed to predict sensitivity based on genomic features, while others have used the chemical properties of the drugs to ascertain their effect. In an effort to integrate these complementary approaches, we developed machine learning models to predict the response of cancer cell lines to drug treatment, quantified through IC50 values, based on both the genomic features of the cell lines and the chemical properties of the considered drugs. Models predicted IC50 values in a 8-fold cross-validation and an independent blind test with coefficient of determination R2 of 0.72 and 0.64 respectively. Furthermore, models were able to predict with comparable accuracy (R2 of 0.61) IC50s of cell lines from a tissue not used in the training stage. Our in silico models can be used to optimise the experimental design of drug-cell screenings by estimating a large proportion of missing IC50 values rather than experimentally measure them. The implications of our results go beyond virtual drug screening design: potentially thousands of drugs could be probed in silico to systematically test their potential efficacy as anti-tumour agents based on their structure, thus providing a computational framework to identify new drug repositioning opportunities as well as ultimately be useful for personalized medicine by linking the genomic traits of patients to drug sensitivity.
△ Less
Submitted 18 March, 2013; v1 submitted 3 December, 2012;
originally announced December 2012.
